New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
Class :
Antimalarials; 4-Quinoline- Methanol
Brand Name :
No Data Available.
Synonyms :
Class :
Antimalarials; 4-Quinoline- Methanol
Dosage forms & Strengths:Â
Adult:Â
Tablet:Â
250 mgÂ
Indicated to treat mild-to-moderate acute malaria due Plasmodium falciparum (chloroquine-susceptible & resistant strains both included) or by Plasmodium vivax
1250 mg orally once as a loading dose
Malaria Prevention
Indicated for the prevention of malaria
250 mg orally each week
Start over a couple of weeks before the arrival of the strain in the endemic area
Continue the medication for weeks after leaving the endemic-prone area
Dosing Consideration
If the treatment of mefloquine does not respond within 48-72 hours, stop the medication, and utilize an alternate therapy
The treatment with mefloquine in acute P.Vivax patients may cause relapse as in these patients; exoerythrocytic parasites are not eliminated
Indicated to treat mild-to-moderate acute malaria due to Plasmodium falciparum (chloroquine-susceptible & resistant strains both included) or by Plasmodium vivax
For more than 6 months, 20-25 mg/kg orally in a single dose or may be divided into 2 doses
Malaria Prevention
For 5-10 kg- 31.25 mg orally every week
10-20 kg- 62.5 mg orally every week
20-30 kg- 125 mg orally every week
30-45 kg- 187.5 mg orally every week
For more than 45 kg- 250 mg orally every week
Start over from 1-2 weeks before arrival in the endemic area
Continue upto 4 weeks after coming from endemic area
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased QTC interval  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of mefloquine 
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine may diminish the therapeutic effect of antiseizure agents
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
mefloquine: it may increase the risk of adverse effects with CYP3A4 inhibitors
the effect of mefloquine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
When mefloquine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
it decreases the effect of anti-seizure agents
1-10%:Â
AnxietyÂ
Difficulty concentratingÂ
HeadacheÂ
InsomniaÂ
LightheadednessÂ
VertigoÂ
VomitingÂ
DiarrheaÂ
Stomach painÂ
NauseaÂ
Visual disturbancesÂ
TinnitusÂ
Frequency undefined:Â
Suicidal depressionÂ
Psychiatric SxÂ
PneumonitisÂ
SeizureÂ
Abnormal ECGÂ
Mefloquine is contraindicated in people hypersensitive to it.
Pregnancy consideration:Â Â
Category BÂ
Breastfeeding warnings:Â Â
Mefloquine is minimally excreted in human breastmilkÂ
Pregnancy category:Â
Patient information leafletÂ
Generic Name: mefloquineÂ
Pronounced: mef-lo-quineÂ
Why do we use mefloquine?Â
Mefloquine treats acute malaria.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
